Pancreatic cancer musters HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition.

被引：0
|
作者：
Bulle, Ashenafi Shiferaw [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1086
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Aberrant HER2 signaling is a therapeutic target in a subset of castration-resistant prostate cancer
    Russo, Joshua W.
    Gao, Xin
    Einstein, David J.
    Bubley, Glenn J.
    Balk, Steven P.
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Inhibition of HER2-Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2-Glycan-Imprinted Nanoparticles
    Dong, Yueru
    Li, Wei
    Gu, Zikuan
    Xing, Rongrong
    Ma, Yanyan
    Zhang, Qi
    Liu, Zhen
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2019, 58 (31) : 10621 - 10625
  • [23] Association of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition.
    Sowalsky, Adam G.
    Wilkinson, Scott C.
    Ku, Anson T.
    Lis, Rosina T.
    King, Isaiah M.
    Low, Daniel
    Trostel, Shana Y.
    Baj, Anna
    Kartal, Sumeyra
    Heyward, Kayla
    Vo, Baohan Thi
    Jansen, Caroline Stewart
    Ye, Huihui
    Harmon, Stephanie A.
    Kissick, Haydn T.
    Pinto, Peter A.
    Choyke, Peter L.
    Turkbey, Baris
    Dahut, William L.
    Karzai, Fatima
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [24] Global MEF2 target gene analysis in cardiac and skeletal muscle reveals novel regulation of DUSP6 by p38MAPK-MEF2 signaling
    Wales, Stephanie
    Hashemi, Sara
    Blais, Alexandre
    McDermott, John C.
    NUCLEIC ACIDS RESEARCH, 2014, 42 (18) : 11349 - 11362
  • [25] Sigma-2-Erastin inhibits PC tumor growth through lipid ROS-DUSP6-MAPK signaling
    Bishnupuri, Kumar S.
    Newcomer, Kenneth F.
    Gong, Qingqing
    Ye, Li
    Vangveravong, Suwanna
    Takchi, Rony
    Keller, Bradley T.
    Spitzer, Dirk M.
    Hawkins, William G.
    CANCER RESEARCH, 2024, 84 (06)
  • [26] Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.
    Siena, Salvatore
    Sartore-Bianchi, Andrea
    Trusolino, Livio
    Martino, Cosimo
    Bencardino, Katia
    Lonardi, Sara
    Leone, Francesco
    Zagonel, Vittorina
    Bertotti, Andrea
    Valtorta, Emanuele
    Siravegna, Giulia
    Amatu, Alessio
    Vanzulli, Angelo
    Regge, Daniele
    Ghezzi, Silvia
    Ciardiello, Fortunato
    Veronese, Silvio
    Comoglio, Paolo Maria
    Bardelli, Alberto
    Marsoni, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [27] Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
    Borrero-Garcia, Luis D.
    del Mar Maldonado, Maria
    Medina-Velazquez, Julia
    Troche-Torres, Angel L.
    Velazquez, Luis
    Grafals-Ruiz, Nilmary
    Dharmawardhane, Suranganie
    BMC CANCER, 2021, 21 (01)
  • [28] Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
    Luis D. Borrero-García
    Maria del Mar Maldonado
    Julia Medina-Velázquez
    Angel L. Troche-Torres
    Luis Velazquez
    Nilmary Grafals-Ruiz
    Suranganie Dharmawardhane
    BMC Cancer, 21
  • [29] Oestrogen receptor and HER2 differentially activate ERK/MAPK signaling pathway in breast cancer: A large cohort study
    Jerjees, D.
    Abduljabbar, R.
    Nolan, C.
    Green, A.
    Ellis, I.
    Rakha, E.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 260 - 260
  • [30] N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer
    Yang, Jing
    Xu, Penghui
    Chen, Zetian
    Zhang, Xing
    Xia, Yiwen
    Fang, Lang
    Xie, Li
    Li, Bowen
    Xu, Zekuan
    CANCER LETTERS, 2023, 558
12345